Why the study?
Does noliprel-forte improve clinical efficacy, LV hypertrophy, and arterial elasticity compared to co-renitec in patients with mild and moderate arterial hypertension?
Does noliprel-forte improve clinical efficacy, LV hypertrophy, and arterial elasticity compared to co-renitec in patients with mild and moderate arterial hypertension?
In patients with mild to moderate hypertension, noliprel-forte and co-renitec provided comparable blood pressure lowering, but noliprel-forte offered superior reduction in left ventricular hypertrophy and improvement in arterial elasticity.
No takes yet. Share an insight, caveat, or question.
Supports noliprel-forte preference for LVH reduction when BP effects are equivalent; extends RCT evidence for fixed combinations on cardiac and vascular remodeling.
The aim of the study was to compare i he clinical efficacy and tolerance of fixed combinations of angiotensin-converting enzyme (ACE) and diuretic noliprel and co-renitec in patients with mild and moderate arterial hypertension with high risk of cardiovascular events. All investigated patients didn't achieved normal AP level with monotherapy. The study was blinded, randomised and performed in parallel groups (20 subjects in each group). The clinical effects were evaluated after 6 months of therapy by 1 tablet of noliprel-forte (4 mg / 12.5 mg) or co-renitec (20 mg / 12.5 mg). The antihypertensive effect was comparable for both dings, but fixed combination of noliprel-forte show advantage in reducing of LV hypertrophy and improvement of arterial elasticity.
Недогода et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: